HPN328 in Advanced Cancers Associated with Expression of Delta Like Canonical Notch Ligand 3 (DLL3)
1-800-641-2422
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 in Patients with Advanced Cancers Associated with Expression of Delta Like Canonical Notch Ligand 3 (DLL3) Who Have Failed Standard Available Therapy
- Sex at Birth: Any
- Age: Adult (18 - 64), Older Adult (65+)
- Accepting Healthy People: No
- Type: Interventional / Therapeutic
- Trial Phase: Phase I
- Conditions Being Studied: Cancer - Solid Tumor
Study Purpose
This study will investigate the maximum tolerated dose, the recommended dose for expansion (RDE), safety, efficacy, and pharmacokinetics of gocatamig alone, gocatamig with Atezolizumab and gocatamig with I-DXd in participants with advanced cancers associated with expression of Delta-like Canonical Notch Ligand 3 (DLL3).
Locations
UH Seidman Cancer Center
11100 Euclid Avenue
Cleveland OH, 44106
- UH IRB: STUDY20201616
- StudyID: HRPN1Y20
- ClinicalTrials.gov: NCT04471727
1-800-641-2422
Questions or concerns? We're here to help.
Non-cancer Trials: 1-833-78TRIAL or Contact Us Online
Cancer Trials: 1-800-641-2422